resTORbio to Present at the Canaccord Genuity 38th Annual Growth Conference
A live audio webcast of the presentation can be accessed on the Investors section of resTORbio’s website at http://ir.restorbio.com/investors. An archived replay will be available for at least 30 days following the presentation.
resTORbio, Inc. is a clinical stage biopharmaceutical company targeting TORC1 and other biological pathways that regulate aging to develop innovative medicines with the potential to extend healthy lifespan. resTORbio’s lead program is selectively targeting TORC1, an evolutionarily conserved pathway that contributes to the decline in function of multiple organ systems, including the immune, cardiovascular and central nervous systems.